Arcus Biosciences (RCUS) Earnings Analysis
Arcus Biosciences (RCUS) has no confirmed upcoming earnings date. Last quarter (2026-02-25) it beat with EPS -0.89 USD vs -1.11 USD est (+19.8%). It has beaten estimates in 1/1 recent quarters (100%). Trailing P/E -9.46.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does RCUS next report earnings?
No confirmed upcoming earnings date is currently scheduled for RCUS. This page updates as the calendar is published.
RCUS earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-02-25 | -0.89 USD | -1.11 USD | +19.8% | Beat |
Beat rate: 1/1 (100%) over reported quarters with consensus data.
RCUS valuation and analyst view
| Trailing P/E | -9.46 |
|---|---|
| Trailing EPS | -2.94258 USD |
| Price / book | 7.17 |
| Dividend yield | 0.00% |
| Market cap | 2.93B |
| Analyst consensus | Buy (15 buy / 3 hold / 0 sell) |
| Avg price target | 34 USD |
Related research pages
Frequently asked questions
When is Arcus Biosciences (RCUS)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for RCUS. This page updates as the calendar is published.
Did RCUS beat earnings last quarter?
In its 2026-02-25 report, RCUS posted EPS of -0.89 USD versus a -1.11 USD estimate — a beat of 19.8%.
What is RCUS's earnings track record?
Over the last 1 reported quarters with consensus data, RCUS beat estimates 1 times (100%).
What is RCUS's current P/E ratio and EPS?
RCUS trades at a trailing P/E of -9.46 on trailing EPS of -2.9425837320574164 USD.
What do analysts rate RCUS?
Analyst consensus is "Buy" across 18 ratings (0 strong buy, 15 buy, 3 hold, 0 sell, 0 strong sell). Average 12-month price target: 34 USD.